Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23529091 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL23529153 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL6060501 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL23529122 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL23529158 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL23529147 | 0.98 | GLRA1 (0.36) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL28900114 | 0.83 | GABRR1 (0.47) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL1989298 | 0.82 | ALDH1A1 (0.39) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL8741818 | 0.82 | ALDH1A1 (0.39) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL16637115 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6383245-B1 | APPLYING NUTRIENT TO PLANT OR SOILS | YAMASHITA THOMAS T (US) | 2002-05-07 | — | — | US | claimed |
| WO-2001077044-A1 | AQUEOUS MINERAL COMPOSITIONS AND METHODS FOR THEIR USE | YAMASHITA THOMAS T (US) | 2001-10-18 | — | — | WO | claimed |
| EP-4077261-B1 | MAGNESIUM CITRATE GLYCINATE CO-SALT | JOST CHEMICAL CO (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114945551-B | Magnesium Glycine citrate co-salt | 约斯特化学公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11148990-B2 | Magnesium citrate glycinate co-salt | JOST CHEMICAL CO. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210188755-A1 | MAGNESIUM CITRATE GLYCINATE CO-SALT | JOST CHEMICAL CO. | 2021-06-24 | — | — | US | disclosed |
| WO-2021126549-A1 | MAGNESIUM CITRATE GLYCINATE CO-SALT | JOST CHEMICAL CO. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20150218342-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| CN-102327617-B | Sulfoalkyl ether-cyclodextrin (SAE-CD) composition and preparation method thereof | CYDEX PHARMACEUTICALS INC | 2014-08-20 | — | — | CN | disclosed |
| CN-103443196-A | Aqueous fluoropolymer dispersion | DAIKIN IND LTD | 2013-12-11 | — | — | CN | disclosed |
| US-8124139-B2 | Compound preparation for quickly reducing oxidative stress and preparation of the same | SINO-US PFICKER PHARMACEUTICALS CO., LTD. (CN) | 2012-02-28 | — | — | US | disclosed |
| CN-101365459-B | Sulfoalkyl ether cyclodextrin compositions and methods for making same | CYDEX PHARMACEUTICALS, INC. (US) | 2011-11-30 | — | — | CN | disclosed |
| US-20100015115-A1 | COMPOUND PREPARATION FOR QUICKLY REDUCING OXIDATIVE STRESS AND PREPARATION OF THE SAME | Sino-US PFICKER PHARMACEUTICALS LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| CN-101365459-A | Sulfoalkyl ether cyclodextrin compositions and methods for making same | CYDEX INC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-7112341-B1 | Pulmonary administration of dry powder formulations for treating infertility | NEKTAR THERAPEUTICS (US) | 2006-09-26 | — | — | US | disclosed |
| US-6939672-B2 | Nucleic acid extraction solution and use thereof | CYTYC CORPORATION (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1169053-A1 | PULMONARY ADMINISTRATION OF DRY POWDER FORMULATIONS FOR TREATING INFERTILITY | Inhale Therapeutic Systems, Inc. (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061178-A1 | PULMONARY ADMINISTRATION OF DRY POWDER FORMULATIONS FOR TREATING INFERTILITY | INHALE THERAPEUTICS SYSTEMS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-H1509-H | Dissolving cryoprecipitate in aqueous solution containing heparin, precipitating protein contaminants with polyethylene glycol, recovering Factor VIII from supernatant | ERAN HARUTYUN (US) | 1995-12-05 | — | — | US | disclosed |
| US-4302445-A | Method for concentrating and purifying antihemophilic factor or factor VIII | INSTITUT MERIEUX (FR) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11148990-B2 | Magnesium citrate glycinate co-salt | SLC6A9, CA9, GRM8 | GLRA1 39/4885SLC6A9 1/4885OR51E2 3126/4885 |
| US-20210188755-A1 | MAGNESIUM CITRATE GLYCINATE CO-SALT | SLC6A9, CA9, GRM8 | GLRA1 39/4885SLC6A9 1/4885OR51E2 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.